The Glaucoma Treatment Market Continued to be driven by Aging Population and Rising Awareness in the Emerging Countries: Ken Research

Glaucoma has been diagnosed as the second leading cause of blindness in the world, according to World Health Organization (WHO) and it has been also been observed that despite of the treatment, 10% of the glaucoma patients still experience loss of vision. Moreover, it has been stated that disease is more prevalent among people above 60 years of age and the growing geriatric population globally, is at higher risk of developing glaucoma. The statistics clearly advocate the need of efficient treatment method for curing glaucoma; however the market has not experienced any presence of such treatment. The medications available in the market are used for management of symptoms.

Global glaucoma treatment market is broadly divided by different drug classes used for management of glaucoma which includes alpha agonist, beta blockers, carbonic anhydrase inhibitors, cholinergic, combined medications, and prostaglandin analogs. Various pharmaceutical giants including Pfizer, Merck, Alcon, Inc., and Allergan provide drugs in their portfolio for treatment of glaucoma in the respective drug classes. The market has also been divided by formulations into three major segments including tablets, solutions, and gels.

Aging population and rising awareness in the emerging economies are the major factors which are expected to drive the glaucoma treatment market during future. However, increasing number of patent expirations during the forecast period is expected to restrain the market during the forecast period.

The publication will be available on Ken Research website in September 2016 and is currently available for pre-order. To know more on the publication and to avail discount on pre-order, contact ankur@kenresearch.com

Scope- Global Glaucoma Treatment Market

Executive Summary
Research Methodology
Global Glaucoma Treatment Market Size
- By Revenue, 2010-2015
- By Number of Drugs Approved, 2010 – 2015
Global Glaucoma Treatment Market Segmentation,
- By Drug Class
  - Alpha Agonist
  - Beta Blockers
  - Carbonic Anhydrase Inhibitors
  - Cholinergic
  - Combined Medications
  - Prostaglandin Analogs
- By Formulation (Tablet, Gel, and Solution)
- By Regions
  - North America
    - United States
    - Canada
  - Europe
    - United Kingdom
    - Germany
    - France
    - Italy
    - Spain
    - Rest of the Europe
  - Asia Pacific
    - India
    - China
    - Japan
    - Rest of Asia Pacific
  - Latin America
    - Mexico
    - Brazil
    - Rest of Latin America
  - Middle East and Africa
    - United Arab Emirates
    - Saudi Arabia
    - Rest of Middle East and Africa

Sales of Patented Glaucoma Treatment Drugs Market (Top 10)
Pipeline Analysis by Phase III Drugs, Phase II Drugs and Phase I Drugs
Patents and Expiry
Snapshot on Generic Drugs used for Glaucoma Treatment market
Trends and Developments in global glaucoma treatment market
Government Regulatory
Porter’s Five Forces Analysis for glaucoma treatment market
Market Share of Players in global glaucoma treatment market (Alcon, Allergan, Pfizer, Merck, Santen, Valeant and Others)
- Brand wise Sales for Patented Drugs
Competitive Landscape for Major Players In glaucoma treatment market (Alcon, Inc., Allergan Inc., Akorn Ophthalmics, Bausch & Lomb Inc., ISTA Pharmaceuticals, Merck & Co. Inc., Vistakon, Inc., Fera Pharmaceuticals, Teva Pharmaceuticals, Pfizer, Santen, and Valeant)
- Portfolio of Patented Drugs and Generic Drugs
Glaucoma Treatment Market Future Outlook and Projections
- By Revenues, 2016- 2020
- By Segments, 2016-2020
Analyst Recommendations
Macroeconomic Factors affecting global glaucoma treatment market